JS-K is primarily utilized in cancer research due to its ability to selectively release nitric oxide (NO) in tumor cells, inducing apoptosis and inhibiting cancer cell proliferation. It is particularly studied for its potential in treating drug-resistant cancers, such as leukemia and multiple myeloma, by targeting glutathione S-transferase (GST) enzymes. Additionally, JS-K is being explored for its role in enhancing the efficacy of chemotherapy and radiation therapy, as NO release can sensitize cancer cells to these treatments. Its application extends to preclinical studies for evaluating its safety and therapeutic potential in various cancer models.